Bioline Rx reported $-2.25M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Arca Biopharma USD -25.07M 5.23M Mar/2025
Bio Path USD -3.21M 631K Mar/2025
Bioline Rx USD -2.25M 1.7M Mar/2026
Capricor Therapeutics USD -27.23M 2.66M Jun/2025